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Background. Molecular markers for sulfadoxine-pyrimethamine (SP) resistance in Plasmodium vivax have been
reported. However, data on the molecular correlates involved in the development of resistance to 4-aminoquinolines
and their association with the in vivo treatment response are scarce.
Methods. We assessed pvdhfr (F57L/I, S58R, T61M, S117T/N, and I173F/L) and pvmdr1 (Y976F and F1076L)
mutations in 94 patients who received amodiaquine (AQ) plus SP in PapuaNewGuinea (PNG).We then investigated
the association between parasite genotype and treatment response.
Results. The treatment failure (TF) rate reached 13%. Polymorphisms in pvdhfr F57L, S58R, T61M, and S117T/N
and in pvmdr1 Y976F were detected in 60%, 67%, 20%, 40%, and 39% of the samples, respectively. The single mutant
pvdhfr 57 showed the strongest association with TF (odds ratio [OR], 9.04; P  .01). The combined presence of the
quadruple mutant pvdhfr 57L58R61M117T and pvmdr1mutation 976F was the best predictor of TF (OR, 8.56;
P  .01). The difference in TF rates between sites was reflected in the genetic drug-resistance profile of the respective
parasites.
Conclusions. The present study identified a new molecular marker in pvmdr1 that is associated with the in vivo
response to AQSP. We suggest suitable marker sets with which to monitor P. vivax resistance against AQSP in
countries where these drugs are used.
More than 50% of all cases of malaria occurring outside
Africa are caused by Plasmodium vivax, and it is esti-
mated that 70–80 million people are infected each year
[1].P. vivaxhas considerable clinical and socioeconomic
influence in countries where this species is endemic, and
the resurgence ofmalaria due toP. vivax ismainly attrib-
utable to the emergence of parasite resistance to com-
monly applied therapies [2, 3].
Chloroquine (CQ)–resistant P. vivax was first reported
in Papua New Guinea (PNG) in 1989 [4]. Thereafter, re-
duced susceptibility of P. vivax to CQ was reported from
several countries where this species is endemic [2].
Sulfadoxine-pyrimethamine (SP) has never been recom-
mended forP. vivaxmalaria.Nevertheless, increasing levels
of P. falciparum resistance to CQ led to the adoption of SP
as a cheap and safe alternative first-line option in many
countries in Southeast Asia, Central and South America,
andOceania, where both species are endemic, and P. vivax
resistance to SP developed rapidly in many areas within
only a fewyears after the initial deployment of SP asmono-
therapy [2, 5, 6].
The hypnozoite, the latent liver stage of P. vivax, can
give rise to a recurrent intraerythrocytic infection be-
tween 3 weeks and several months after the initial infec-
tion, depending on the strain. Therefore, in vivo assess-
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ment of drug efficacy is complicated by difficulties in clearly
differentiating between treatment failures (TFs; i.e., true recru-
descences originating from asexual blood stage parasites), re-
lapses (i.e., red blood cell infection originating from hypnozo-
ites), and newly acquired infections. Moreover, comparison of
data is aggravated by the lack of studies that have followed stan-
dardized protocols. As in the case of Plasmodium falciparumma-
laria, the assessment ofmolecular drug-resistancemarkers could
be a valuable complementary tool for the mapping and regular
monitoring of drug-resistant P. vivax malaria [7, 8]. Several
genes related to resistance to commonly used drugs have been
described in P. falciparum. Orthologous genes of pfdhfr (P. fal-
ciparum dihydrofolate reductase), pfdhps (dihydropteroate syn-
thase), pfcrt (chloroquine resistance transporter gene), and
pfmdr1 (multiple-drug–resistance gene 1) have been found in P.
vivax, notably pvdhfr [9], pvdhps [10], pvcg10 [11], and pvmdr1
[12]. Although no evidence could be found for an association
between point mutations in both pvcg10 and pvmdr1 and CQ
resistance in P. vivax field isolates [11, 13], several laboratory
studies have shown that pyrimethamine resistance is associated
with a specific single-nucleotide polymorphism (SNP) accumu-
lation in pvdhfr that leads to reduced enzyme affinity to the drug
and that corresponds to reduced susceptibility to py-
rimethamine in vitro [14–18]. This association could be con-
firmed in epidemiological studies investigating the association
between the genetic pvdhfr background and the in vivo response
to antifolates [19–21]. Likewise, reduced in vitro susceptibility
to sulfadoxine [22, 23] and an association with the clinical re-
sponse to SP have been shown to be associated with SNPs in
pvdhps [10, 24].
In PNG, where all 4 Plasmodium species affecting humans are
found, themajority of infections are caused by P. falciparum and
P. vivax, and mixed infections are common [25]. After a long
history of the use of 4-aminoquinolines against malaria, reports
of reduced in vivo efficacy of 4-aminoquinolines against P. fal-
ciparum andP. vivaxmalaria began to accumulate since themid-
1970s and the 1980s, respectively [26, 27]. The extent of this
reduction in efficacy becameunacceptably great in the 1990s [28,
29]. Despite low levels of SP use in PNG (where it was used only
in combination with quinine to treat severe and TF malaria
cases), P. falciparum resistance to SP, as well as a reduced efficacy
of SP against P. vivax, has been described in the Madang prov-
ince [30–33].
The first-line policy against uncomplicated malaria in PNG
was changed to the combination of amodiaquine (AQ) or CQ
plus SP in 2000. To assess the clinical efficacy of the current
first-line regimen against P. vivaxmalaria, we conducted in vivo
drug efficacy studies in 3 different areas in PNG between 2004
and 2005, using standard clinical classifications set forth by the
revised World Health Organization (WHO) protocol [34]. In
the present study, we assessed P. vivax mutations in pretreat-
ment samples obtained frompatients with amonoinfectionwho
received AQ in combination with SP and then investigated the
association between parasite genotype and treatment response.
SUBJECTS, MATERIALS, AND METHODS
Subjects and therapeutic classification. In vivo drug efficacy
studies performed according to the revisedWHO protocol were
conducted betweenOctober 2004 and April 2005 in the Karimui
area (Simbu Province), the SouthWosera area (East Sepik Prov-
ince), and the North Coast area of Madang (Madang Province),
as described in detail elsewhere [34].
Patients were classified as TF cases when they (1) experienced
clinical deterioration in the presence of P. vivax parasitemia, (2)
developed parasitemia between 3 and 28 days after treatment
initiation and had an axillary temperature of 37.5°C, or (3)
developed parasitemia between 7 and 28 days after treatment
initiation, irrespective of clinical conditions [35]. Patients with-
out clinical signs and without recurrent asexual parasites up to
28 days after treatment initiation were classified as having an
adequate clinical and parasitological response (ACPR).
Laboratory analyses. Blood samples obtained by finger-
prickwere collected into EDTAMicrotainer tubes (BectonDick-
inson), and DNA was extracted using the QIAamp DNA Blood
Kit (Qiagen) according to the manufacturer’s instructions.
Detection of SNPs in pvdhfr (F57L/I, S58R, T61M, S117T/N,
and I173F/L) and pvmdr1 (Y976F and F1076L) was performed
using a LightCycler system (Roche) and fluorescence resonance
energy transfer technology. Primers and probes (table 1) were
designed and synthesized by TIB Molbiol (DNA Synthesis Ser-
vice). The polymerase chain reaction mixture and assay condi-
tions were used as described in detail elsewhere [12, 36]. DNA
sequencing was used to confirm the presence of codon L or I at
position 57 in pvdhfr.
Statistics. Statistical analyses were performed using STATA
software (version 8.2; Stata Corporation). The strength of an
association was evaluated by calculating odds ratios (ORs). We
used a 2 test or Fisher’s exact test and, where applicable, logis-
tical regression analysis, to assess the relationship between single
or multiple mutations and TF, taking into account other vari-
ables known to be associated with treatment outcome.
RESULTS
In vivo response to AQSP. Baseline characteristics of all
children who had a P. vivaxmonoinfection on the day of admis-
sion to the health center are presented in table 2. A total of 98
childrenwere treatedwithAQSP. TFwas seen in 13 (13.3%) of
all 98 children with P. vivax monoinfection (table 2). The ma-
jority of patients (11/13 [84.6%]) were classified as having par-
asitological TF at day 28 after treatment initiation, 1 patient ex-
perienced treatment failure at day 6, and 1 experienced
treatment failure at day 20. There was a significant difference in
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TF rates between sites: 33% in the North Coast area of Madang,
5% in the Karimui area, and 0% in the Wosera area.
Prevalence of and relationship between pvdhfr and pvmdr1
mutations. Mutation analyses were accomplished for 94
(95.9%) of all 98 samples. Polymorphisms in pvdhfr codons
F57L, S58R, T61M, and S117T/N and in pvmdr1 codon Y976F
were detected in 60%, 67%, 20%, 40%, and 39% of samples,
respectively. Depending on the codon position, a pure mutant
allele was found inmost of the samples (14%–57%), whereas, in
6%–17% of the samples, a mutant allele was found in conjunc-
tion with the wild-type allele. None of the other SNPs (i.e.,
pvdhfr F57I, pvdhfr I173F/L, and pvmdr1 F1076L) was detected
Table 1. Sequences of primers and oligonucleotide probes used for the detection of pvdhfr (F57L/I,
S58R, T61M, S117T/N, and I173F/L) and pvmdr1 (Y976F and F1076L) mutations.
Gene, primer or probe Sequence Position SNP
pvdhfra
Primer
pvdhfr S 5'-TCTGGGCAATAAGGGGACT-3' 114–132
pvdhfr A 5'-AGTTTCTACTTAGGCATTCCCTAT-3' 559–536
Probe
Sensor 57/8 5'-GTAGGTCGTCACCGAGCTGAAGT FL-3' 189–167 57, 58
Anchor 57/8 5'-CTTCATATCGACGGAGTTGCATTTCCATG PH-3' 165–137 61
Sensor [G] 5'-GATGCTCTCCCAGCTGCTTC FL-3' 363–344 117
Anchor 117 5'-CCCCATGACCACGACGTTTTGCAG PH-3' 342–319 117
Sensor 172V 5'-TGTGCTCCCCCAATGACGA FL-3' 530–512 173
Anchor 172/173 5'-GCATTTGTAGTACTTCAGCTTCTTTAAGAGC PH-3' 510–480 173
pvmdr1b
Primer
pvmdr1 5'-ATAGTCATGCCCCAGGATTG-3' 2753–2772
pvmdr1 447AS 5'-ACCGTTTGGTCTGGACAAGTAT-3' 3535–3516
Probe
Sensor Phe 5'-CATAAAAATGAAGAACGTTCCGGTC FL-3' 2940–2916 976
Anchor 976 5'-GTACAGCCGCCACGATAGGGCAGAA PH-3' 2914–2890 976
Sensor Leu 5'-AGTGCCCAACTTTTCATTAACAG FL -3' 3217–3239 1076
Anchor 1076 5'-TTGCCTACTGGTTTGGTTCCTTCCT PH-3' 3242–3266 1076
NOTE. pvdhfr, Plasmodium vivax dihydrofolate reductase; pvmdr1, P. vivax multiple-drug–resistance gene 1; PCR,
polymerase chain reaction.
a GenBank accession no. X98123 (PCR product, 422 bp).
b GenBank accession no. AY618622 (PCR product, 763 bp).
Table 2. Baseline characteristics and treatment outcomes for patients at enrollment who were receiving amodiaquine
plus sulfadoxine-pyrimethamine against Plasmodium vivax malaria, by study site.
Characteristic
North Coast areaa
(n  33)
Karimui areab
(n  39)
South Wosera areac
(n  26)
All
(n  98)
Weight, mean (95% CI), kg 15.9 (8.0–23.8) 12.6 (11.7–13.5) 11.8 (10.3–13.2) 14.1 (11.2–16.9)
Age, mean (95% CI), years 2.3 (1.9–2.8) 3.2 (2.8–3.6) 3.2 (2.5–3.9) 2.9 (2.6–3.2)
Sex, no. of females (%) 20 (60.6) 15 (38.5) 9 (34.6) 44 (45.8)
Temperature, mean (95% CI),°C 37.1 (36.6–37.76) 38.6 (38.3–38.8) 37.0 (36.4–37.7) 37.7 (37.4–38.0)
Hemoglobin level, mean (95% CI), g/dL 10.2 (9.4–11.1) 10.5 (9.8–11.1) 9.3 (8.6–9.9) 10.1 (9.7–10.5)
Parasite density,d geometric mean (range) 4688 (300–41280) 3810 (40–36600) 4994 (160–50640) 4930 (40–50640)
Classification, no. (%) of patients
ACPR 22 (66.7) 37 (94.9) 26 (100) 85 (86.7)
Treatment failure 11 (33.3) 2 (5.1) 0 13 (13.3)
NOTE. ACPR, adequate clinical and parasitological response; CI, confidence interval.
a Madang province.
b Simbu province.
c East Sepik province.
d Per microliter.
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as a mutated allele in any of the samples. Eight different pvdhfr
alleles were observed in single-clone infections (76.7%), with the
wild type 57F58S61T117S, the double mutant 57L58R,
and the quadruple mutant 57L58R61M117L/I being the
most prevalent haplotypes (30%, 23%, and 14%, respectively).
Twenty-two (23.4%) of the samples contained mixed alleles at
varying codon positions indicating polyclonal infections (table
3). It is worthmentioning that (1) themutation F57Lwas always
linked to S58R and (2) the T61Mmutation was always linked to
the triple mutation F57LS58RS117T. In contrast to S117T,
which was found in single, double, triple, and quadruple muta-
tions in pvdhfr, S117N was observed only in single or double
mutations.
Association between pvdhfr and pvmdr1 alleles and treat-
ment outcome. We pooled the data from all 3 study sites and
evaluated the association between infections with single and
combinedmutant alleles in pvdhfr and pvmdr1 and the response
to treatment. All patient isolates were coded according to the
presence or absence of mutant alleles, and isolates showing both
wild-type and mutant alleles were considered to be mutant.
Likewise, infecting genotypes were coded according to the most
highly mutated pvdhfr and pvmdr1 alleles present in the sample.
In the present study, 2 variables—fever (axillary temperature,
37.5°C) and parasite density on the day of study enrollment—
were not associated with an increased risk of TF associated with
P. vivax malaria. Risk of TF tended to decrease with increasing
patient age (OR, 0.55; 95% confidence interval [CI], 0.31–0.97;
P  .02). Regarding single molecular markers in pvdhfr, the
presence of mutated codon position 57L, 58R, or 117T was in-
dependently associated with an increased risk of TF (table 4).
The same observation was made with infections harboring the
mutation pvmdr1 976F. This relationship was further confirmed
by the observation of a decreased risk of TF for infections having
the wild-type allele 976Y, although the association did not reach
statistical significance.
We could discriminate between 14 different pvdhfr/pvmdr1
genotypes (table 4). Of those genotypes, 7 were observed in as-
sociation with TF, whereas the remaining 7 were found exclu-
sively in patients with an ACPR. Regarding pvdhfr genotypes
alone, the risk of TF was clearly associated with the numbers of
mutations present in an infection. However, the only significant
association with a negative treatment outcome was noted for
infecting genotypes having pvdhfr quadruple mutations com-
bined with the pvmdr1mutation 976F.
We further investigated whether the difference in treatment
outcome between study sites was reflected in the drug-resistance
marker profile of the corresponding parasite populations. Re-
garding polymorphisms in pvdhfr, there was amarked difference
between sites for the mutated positions 57L, 58R, and 117T/N.
Similarly, when compared with the prevalence of the 2 sites with
lower rates of TF, the mutated locus pvmdr1 976F had a signifi-
cantly higher prevalence in the North Coast area (table 5). Cor-
respondingly, the prevalence of the wild-type allele 976Y was
lowest at this site with the highest level of in vivo resistance. A
similar finding was noted when the genotype frequencies were
compared. The different levels of treatment response were not
reflected only in a varying prevalence of the number of muta-
tions in pvdhfr (P  .04, by 2 test). There was a significant
difference between sites in terms of the prevalence of the wild-
type pvdhfr/pvmdr1 genotype, which showed a trend toward an
increase in prevalence with a decreasing TF rate (P  .02, by 2
test). The inverse trend was observed with the 2 genotypes hav-
ing a mutated pvmdr1 976F combined with the pvdhfr double
(57L58R) or quadruple (57L58R61M117T) mutation, for
whichprevalences increasedwith increasing rates of in vivoTF rates
(P  .002 and P  .003, respectively, by 2test) (data not
shown).
DISCUSSION
After only 4 years of effective implementation in PNG, the effi-
cacy of the new first-line regimen of either AQ or CQ plus SP
Table 3. pvdhfr haplotypes in 94 pretreatment samples from
patients in Papua New Guinea who received amodiaquine plus
sulfadoxine-pyrimethamine against Plasmodium vivax malaria.
Category
pvdhfr
polymorphisma Samples,
no. (%)
(n  94)57 58 61 117
Samples with a single
pvdhfr haplotype
(n  72 [76.6%]) F S T S 28 (29.8)
F S T N 2 (2.1)
F R T S 1 (1.1)
F R T T 2 (2.1)
F R T N 3 (3.2)
L R T S 22 (23.4)
L R T T 1 (1.1)
L R M T 13 (13.8)
Samples with mixed
pvdhfr haplotypes
(n  22 [23.3%]) F S/R T S 1 (1.1)
F S T S/T 1 (1.1)
L R T S/T 4 (4.3)
L R T S/N 5 (5.3)
L R T/M S/T 2 (2.1)
L R T/M T 1 (1.1)
F/L S/R T S 4 (4.3)
F/L S/R T S/N 1 (1.1)
F/L S/R T/M S/N 1 (1.1)
F/L S/R T/M S/T 2 (2.1)
NOTE. pvdhfr, P. vivax dihydrofolate reductase.
a Boldfaced letters denote mutated alleles.
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against uncomplicated malaria has reached unacceptably low
levels in both species [34]. In the present study, we investigated
the association between drug-resistance markers in pvdhfr and
pvmdr1 in patients with a P. vivax monoinfection and the ther-
apeutic outcome achieved with the newly introduced combina-
tion regimen. We measured high prevalences of mutated key
markers in both genes and demonstrated an association between
the infecting pvdhfr/pvmdr1 genotype and the in vivo treatment
response. Furthermore, the different TF rates observed at differ-
ent study sites were reflected in the genetic drug-resistance pro-
file of the corresponding parasite populations. This is probably
themost important finding, because it validates the usefulness of
molecular markers in monitoring P. vivax resistance to antima-
larial drugs to aid policy makers in the development of rational
treatment strategies.
Regarding all SNPs analyzed in pvdhfr (F57L/I, S58R, T61M,
S117T/N, and I173F/L) and pvmdr1 (Y976F and F1076L), we
found a high prevalence of infections harboring parasites with
mutated gene loci (i.e., 20%–67% of samples, depending on the
locus analyzed). Furthermore, we observed a high degree of di-
versity of different pvdhfr genotypes in our sample set, which
derived from 3 different areas within the same country. In most
Table 4. Association between single-mutated gene loci in pvdhfr and pvmdr1 and infecting pvdhfr/
pvmdr1 genotypes and treatment response to amodiaquine plus sulfadoxine-pyrimethamine.
Polymorphism/genotype Prevalencea
Treatment response
OR (95% CI) PACPR TF
Polymorphic SNP siteb
pvdhfr 57L 56 (59.6) 45 (80.4) 11 (19.6) 9.04 (1.12–73.32) .01c
pvdhfr 58R 63 (67.0) 52 (82.5) 11 (17.5) 6.35 (0.78–51.61) .03c
pvdhfr 61M 19 (20.2) 14 (73.7) 5 (26.3) 3.47 (0.96–12.52) .07c
pvdhfr Mut117d 38 (40.4) 31 (81.6) 7 (18.4) 2.30 (0.67–7.89) .18c
pvdhfr 117T 26 (27.7) 19 (73.1) 7 (26.9) 4.64 (1.32–16.32) .02c
pvdhfr 117N 12 (12.8) 12 (100) 0 . . .e .14c
pvmdr1 976Ff 37 (39.4) 29 (78.4) 8 (21.6) 3.66 (1.01–13.18) .04c
pvmdr1 976Yg 68 (72.3) 62 (91.2) 6 (8.8) 0.32 (0.09–1.11) .08c
pvdhfr/pvmdr1 genotypeh
Wild-type/976Yi 19 (20.2) 18 (94.7) 1 (5.3) 0.29 (0.04–2.40) .18j
Wild-type/976Fk 9 (9.6) 9 (100) 0 . . .l
Single 117/976Y 2 (2.1) 2 (100) 0 . . .l
Single 117/976F 1 (1.1) 1 (100) 0 . . .l
Single 58/976Y 1 (1.1) 1 (100) 0 . . .l
Single 58/976F 1 (1.1) 1 (100) 0 . . .l
Double 57–58/976Y 16 (17.0) 15 (93.8) 1 (6.2) 0.40 (0.05–3.32) .34j
Double 57–58/976F 10 (10.6) 7 (70.0) 3 (30.0) 3.17 (0.70–14.29) .16j
Double 58–117/976Y 4 (4.3) 4 (100) 0 . . .l
Double 58–117/976F 1 (1.1) 1 (100) 0 . . .l
Triple 57–58-117/976Y 5 (5.3) 4 (80.0) 1 (20.0) 2.17 (0.21–22.57) .54j
Triple 57–58-117/976F 6 (6.4) 5 (83.3) 1 (16.7) 1.60 (0.17–15.59) .70j
Quadruple 57–58-61–117/976Y 10 (10.6) 9 (90.0) 1 (10.0) 0.67 (0.08–5.75) .70j
Quadruple 57–58-61–117/976F 9 (9.6) 5 (55.6) 4 (44.4) 8.56 (1.82–40.24) .01j
Total 94 (100) 82 (87.2) 12 (12.8)
NOTE. Data are no. (%) of patients, unless indicated otherwise. ACPR, adequate clinical and parasitological re-
sponse; CI, confidence interval; OR, odds ratio; pvdhfr, Plasmodium vivax dihydrofolate reductase; pvmdr1, multiple-
drug–resistance gene 1; SNP, single-nucleotide polymorphism; TF, treatment failure.
a Prevalence of polymorphic SNP site or genotype.
b In pvdhfr and pvmdr1.
c Determined by standard 2 analysis or Fisher’s exact test.
d Mut117, either 117T or 177N.
e 117N was not found in patients who experienced TF.
f 976F denotes a mutated allele.
g 976Y denotes a wild-type allele.
h The genotype is assigned according to the mutated alleles (i.e., a mixed allele is coded as a mutant). Presentation
is pvdhfr mutation/pvmdr1 polymorphism.
i Wild-type allele.
j Determined by likelihood ratio test.
k Mutated allele.
l These genotypes were not found in patients who experienced TF.
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of the samples, we detected pvdhfrwild-type alleles (30%of sam-
ples) and double (33%) and quadruple mutations (20%),
whereas the rates of single and triple mutations were lower (5%
and 12%, respectively).Of the genotypeswith doublemutations,
the allelic variant 57L58Roccurredmost often in PNG(84%of
genotypes). The prevalence of infections with the mutation
Y976F in pvmdr1 was also high (39% of samples), and the mu-
tation was found in all possible combinations with the different
genotypes detected in pvdhfr.
Ourobservations are consistentwith the results of similar studies
performed in different countries where P. falciparum and P. vivax
are sympatric andwhere increasing levels of CQ resistance have led
to a policy change involving a switch to the alternative low-cost
option of using SP. In these regions, in vivoP. falciparum resistance
to SP developed rapidly after the initial deployment of SP asmono-
therapy [2, 5], and itwas paralleled by the development of in vivoP.
vivax resistance [6, 21]. Results were further corroborated by the
recent demonstration of a similar molecular mechanism of antifo-
late resistance in both species, one that is conferred by single point
mutations in the target enzymes of antifolates and is driven by ex-
ertion of selective drug pressure [10, 14, 17, 37]. Different epidemi-
ological studies determining the molecular pvdhfr background in
field isolates originating from various regions worldwide, such as
Thailand [7, 20], Indonesia [15, 19, 21], Cambodia [38],Myanmar
[39], India [40, 41], andEthiopia [42], have shown that previous SP
use is correlated with the prevalence rates of resistant pvdhfr alleles.
Moreover, the association between infecting pvdhfr alleles and
the treatment outcome associated with SP monotherapy could be
demonstrated in Thailand [20] and Indonesia [19, 21].
A similar development of P. vivax resistance to SP seems to
have taken place in PNG, although SP was introduced in com-
bination with 4-aminoquinolines. The low susceptibility to SP
noted in both species in PNG has been documented elsewhere
[32] and most probably has arisen because of former drug pres-
sure exerted by mass treatment campaigns with pyrimethamine
(in combination with CQ) in the late 1960s and 1970s and be-
cause of the use of SP in combination with quinine as a second-
line regimen against TF and severe malaria. Therefore, the high
frequency of pyrimethamine-specificmolecularmarkers that we
measured in P. vivax populations is not surprising. Moderate
rates ofmutation of resistancemarkers inP. falciparumdhfr (i.e.,
S108N and C59R [43]), which had reached almost fixed levels in
2003 [44], provide further evidence supporting the hypothesis
thatmoderately resistant dhfr alleles had already occurred before
the effective implementation of SP as part of the standard first-line
treatment and that the rapid emergence of alleles with high-level
resistance could not be curbed by combining SP with AQ or CQ.
Supplementation of in vivo efficacy data with molecular cor-
relates could be a valuable tool inmonitoring P. vivax resistance,
particularly because unambiguous determination of TF rates is
aggravated by difficulties in distinguishing relapses and new
infections. Recent advances in the understanding of the
mechanisms underlying SP resistance in P. vivax have paved the
way for the molecular monitoring of resistance against antifo-
lates in this species. However, molecular resistance markers for
4-aminoquinolines have not been reported for P. vivax up to the
present. Although orthologous genes for pfcrt and pfmdr1, 2 im-
portant genes involved in CQ-resistant falciparum malaria (re-
viewed in [45] and [46]), have been discovered, and although
nonsynonymous point mutations have been described, an asso-
ciation between in vivo resistance and these SNPs or other ge-
netic alterations, such as gene amplification or varying levels of
expression, could not be established until now [10–12].
To suggest useful markers for the molecular monitoring of P.
vivax resistance to AQSP, we performed a baseline assessment
of the molecular profile in P. vivax dfhr andmdr1, and we inves-
tigated the association between infecting pvdhfr/pvmdr1 geno-
types and the in vivo treatment response. Regarding pvdhfr, the
single-point mutations 57L, 58R, and 117T, as well as the total
number of mutations, were all independently associated with an
increased risk of TF. These results are in concordance with pre-
vious results showing that (1) the parasite reduction ratio noted
48 h after initiation of treatment with SP was lower in patients
harboring triple dhfr mutants than in those harboring double
mutants [20], and (2) individuals infected with quadruple dhfr
mutants had a higher risk of experiencing TF when receiving SP
Table 5. Prevalence of polymorphisms in pvdhfr and pvmdr1
and corresponding treatment failure (TF) rates for amodiaquine
plus sulfadoxine-pyrimethamine at 3 different study sites in
Papua New Guinea.
Finding
North
Coast
area
(n  29)
Karimui
area
(n  39)
South
Wosera
area
(n  26) P a
Mutated SNP site
pvdhfr 57L 82.8 46.2 53.9 .01
pvdhfr 58R 89.7 53.9 61.5 .01
pvdhfr 61M 27.6 10.3 26.9 .13
pvdhfr Mut117b 55.2 25.6 46.2 .04
pvdhfr 117T 41.4 18.0 26.9 .10
pvdhfr 117N 13.8 7.7 19.2 .39
pvmdr1 976F 69.0 25.6 26.9 .001
Wild-type SNP site
pvdhfr 57F 31.0 59.0 53.9 .06
Pvdhfr 58S 24.1 53.9 46.2 .05
pvdhfr 61T 86.2 92.3 76.9 .21
pvdhfr 117S 72.4 87.2 65.4 .10
pvmdr1 976Y 48.3 82.1 84.6 .002
TF rate 33.3 5.1 0.0 .001
NOTE. Data are percentages denoting either the prevalence of polymor-
phisms or the TF rate in each area. pvdhfr, Plasmodium vivax dihydrofolate
reductase; pvmdr1, multiple-drug–resistance gene 1; SNP, single-nucleotide
polymorphism.
a As determined by  2(2) analysis.
b Mut117, either 117T or 117N.
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[19, 21]. Regarding the combinations ofmutations in pvdhfr, the
observations that (1) mutation 117N was never observed in dhfr
triple or quadruple mutants, (2) triple and quadruple mutants
always had themutation 117T, (3) 57L was always linked to 58R,
and (4) 61M was seen only in quadruple mutants were all in
agreement with previous data. The most prevalent dhfr geno-
types reported in previous studies included single 117, double
58117, triple 1175857, and quadruple 117615857
mutants, and, because of this frequently observed allele struc-
ture, the stepwise accumulation of mutations in pvdhfr was sug-
gested to be similar to that in P. falciparum, in which low-level
pyrimethamine resistance is conferred by the single pfdhfr mu-
tation 108N (corresponding to pvdhfr 117N) and in which drug
selection processes leading to the addition of 59R and/or 51I
(corresponding to pvdhfr 58R and 57L/I) increase resistance to
SP [20, 21, 47]. Our data from PNG that showed a high fre-
quency of infections with the double mutant 57L58R seem to
be inconsistent with this hypothesis. Nevertheless, the same
doublemutant has been previously described in Thai and Indian
field isolates [20, 40], and Hastings et al. [15] reported preva-
lence rates of 5.3% in the Wosera area in 1999 and 8% in the
North Coast area in 2000. Moreover, using a yeast expression
system for the investigation of in vitro drug susceptibility of dif-
ferent allelic pvdhfr variants, the same authors showed that indi-
viduals with the double mutant 57L58R were less susceptible
to pyrimethamine than the population expressing the wild-type
allele.
Regarding pvmdr1, we could confirm previous results that
demonstrated the presence of the polymorphic mdr1 locus
Y976F in field isolates [12]. Furthermore, we found the muta-
tion to be a strong independent predictor of TF associated with
the use of AQSP. To our knowledge, these are the first data to
indicate that pvmdr1 plays an important role in mediating in
vivo drug resistance in P. vivax. This finding is in contrast with
recent studies, in which an association of pvmdr1 polymor-
phisms with P. vivax resistance to CQ andmefloquine could not
be demonstrated [13, 48]; themost likely reason for this inability
to demonstrate an association is that these studies used small
sample sizes and were not specifically designed to demon-
strate an association between pvmdr1 polymorphisms and the in
vivo treatment response. However, the role of pvmdr1 in confer-
ring resistance to different drugs remains to be clarified. The
situation may be equally as complex as that associated with
falciparummalaria, in which different SNPs and/or gene ampli-
fication was shown to be associated with resistance to
4-aminoquinolines, amino alcohols, and artemisinin deriva-
tives, respectively [49, 50].
The good predictive value of the single markers analyzed in
both genes was further confirmed by investigation of the associ-
ation between the combined pvdhfr/pvmdr1 genotype and the
treatment response, forwhich the highest risk of TFwas found to
be significantly associatedwith an infecting genotypewith a qua-
druple mutation in pvdhfr plus a 976F mutation in pvmdr1. The
observation of TF occurring in association with infections in-
volving wild-type alleles may well be a consequence of technical
constraints resulting from limitations in differentiating true re-
crudescences from relapses and/or new infections, which may
have lead to an overestimation of true TF rates.
In spite of these limitations and the fact that a drug-resistant
P. vivax phenotype is most likely mediated by multigenic pro-
cesses, we think that the set of SNPs included in our study is
sufficient to monitor parasite resistance under the current first-
line regimen. The difference in TF rates between sites was not
only reflected in the different prevalence rates of key markers
that have shown an association with treatment response, but it
was also reflected in the different frequencies of highly mutated
and/or wild-type pvdhfr/pvmdr1 genotypes circulating at the re-
spective sites. These findings strongly support the usefulness of
molecular markers inmonitoring the dynamics of P. vivax resis-
tance and, thus, their important role in complementing in vivo
efficacy data to determine the most appropriate and feasible
drug policy against vivaxmalaria. For the time being, we propose
to use polymorphisms in pvdhfr F57L, S58R, and S117T/N and
in pvmdr1 Y976F for the molecular assessment of P. vivax resis-
tance to AQSP. However, the inclusion of other SP-relevant
markers (e.g. polymorphisms in pvdhps) and as-yet-unidentified
markers involved in resistance to other antimalarials may be-
come necessary for the longitudinal monitoring of resistance in
the future, in particular when a policy change will recommend
new classes of drugs.
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